Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co ROE

The Return on Equity (ROE) of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 20, 2026 is -17.78 %. In the previous year, Return on Equity (ROE) was -9.26 % — a change of 92.04% (lower).

ROE

-17.78 %

YoY

92.04%

Last updated:

In 2025, Tibet Duo Rui Pharmaceutical Co's return on equity (ROE) was -17.78 %, a 92.04% increase from the -9.26 % ROE in the previous year.

The Tibet Duo Rui Pharmaceutical Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
58.38 CNY
Jan 1, 2019
47.69 CNY
Jan 1, 2020
37.96 CNY
Jan 1, 2021
8.64 CNY
Jan 1, 2022
2.73 CNY
Jan 1, 2023
2.44 CNY
Jan 1, 2024
-9.26 CNY
Jan 1, 2025
-17.78 CNY
The Tibet Duo Rui Pharmaceutical Co ROE history
YEARROEYoY
-17.78 %+92.04%
-9.26 %-479.27%
2.44 %-10.50%
2.73 %-68.42%
8.64 %-77.24%
37.96 %-20.40%
47.69 %-18.32%
58.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Tibet Duo Rui Pharmaceutical Co's Return on Equity (ROE)

Tibet Duo Rui Pharmaceutical Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Tibet Duo Rui Pharmaceutical Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Tibet Duo Rui Pharmaceutical Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Tibet Duo Rui Pharmaceutical Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Return on Equity (ROE) of Tibet Duo Rui Pharmaceutical Co is -17.78 % in 2025.

Return on Equity (ROE) of Tibet Duo Rui Pharmaceutical Co changed from -9.26 % to -17.78 %, representing a 92.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Tibet Duo Rui Pharmaceutical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Tibet Duo Rui Pharmaceutical Co